1. Windsor, JW, Kaplan, GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep 2019; 21: 40.
Google Scholar | Crossref | Medline2. Ananthakrishnan, AN, Kaplan, GG, Ng, SC. Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century. Clin Gastroenterol Hepatol 2020; 18: 1252–1260.
Google Scholar | Crossref | Medline3. Kaplan, GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015; 12: 720–727.
Google Scholar | Crossref | Medline4. Troncone, E, Marafini, I, Del Vecchio Blanco, G, et al. Novel therapeutic options for people with ulcerative colitis: an update on recent developments with Janus kinase (JAK) inhibitors. Clin Exp Gastroenterol 2020; 13: 131–139.
Google Scholar | Crossref | Medline5. Levin, AD, Wildenberg, ME, van den Brink, GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis 2016; 10: 989–997.
Google Scholar | Crossref | Medline6. Casellas, F, Robles, V, Borruel, N, et al. Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFalpha treatment. J Crohns Colitis 2012; 6: 881–886.
Google Scholar | Crossref | Medline7. Vogelaar, L, Spijker, AV, van der Woude, CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2009; 2: 101–109.
Google Scholar | Crossref | Medline8. Ruder, B, Atreya, R, Becker, C. Tumour necrosis factor alpha in intestinal homeostasis and gut related diseases. Int J Mol Sci 2019; 20: 1887.
Google Scholar | Crossref | Medline9. Sandborn, WJ, Hanauer, SB, Katz, S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088–1094.
Google Scholar | Crossref | Medline | ISI10. Rutgeerts, P, Sandborn, WJ, Fedorak, RN, et al. Onercept for moderate-to-severe Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 888–893.
Google Scholar | Crossref | Medline | ISI11. European Medicines Agency (EMA) . Idacio summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/idacio-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar12. European Medicines Agency (EMA) . Remicade summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar13. European Medicines Agency (EMA) . Humira summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar14. US Food and Drug Administration (FDA) . Cimzia prescribing information, https://www.cimzia.com/themes/custom/cimzia/docs/CIMZIA_full_prescribing_information.pdf (accessed 14 January 2021).
Google Scholar15. European Medicines Agency (EMA) . Simponi summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar16. European Medicines Agency (EMA) . Simponi summary of opinion. https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-simponi_en-0.pdf (accessed 14 January 2021).
Google Scholar17. European Medicines Agency (EMA) . Inflectra summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/inflectra-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar18. European Medicines Agency (EMA) . Remsima summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar19. European Medicines Agency (EMA) . Flixabi summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/flixabi-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar20. European Medicines Agency (EMA) . Amgevita summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/amgevita-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar21. European Medicines Agency (EMA) . Imraldi summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/imraldi-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar22. European Medicines Agency (EMA) . Zessly summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/zessly-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar23. European Medicines Agency (EMA) . Hyrimoz summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/hyrimoz-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar24. European Medicines Agency (EMA) . Hefiya summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/hefiya-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar25. European Medicines Agency (EMA) . Halimatoz summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/halimatoz-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar26. European Medicines Agency (EMA) . Hulio summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/hulio-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar27. European Medicines Agency (EMA) . Amsparity summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/amsparity-epar-product-information_en.pdf (accessed 14 January 2021).
Google Scholar28. European Medicines Agency (EMA) . Yuflyma summary of opinion, https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-yuflyma_en.pdf (accessed 14 January 2021).
Google Scholar29. Fine, S, Papamichael, K, Cheifetz, AS. Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol 2019; 15: 656–665.
Google Scholar30. Adegbola, SO, Sahnan, K, Warusavitarne, J, et al. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci 2018; 19: 2244.
Google Scholar | Crossref31. Ashton, JJ, Mossotto, E, Ennis, S, et al. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr 2019; 8: 56–69.
Google Scholar | Crossref | Medline32. Flamant, M, Roblin, X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol 2018; 11: 1756283X17745029.
Google Scholar | SAGE Journals33. Shivaji, UN, Sharratt, CL, Thomas, T, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2019; 49: 664–680.
Google Scholar | Crossref | Medline34. Holbrook, J, Lara-Reyna, S, Jarosz-Griffiths, H, et al. Tumour necrosis factor signalling in health and disease. F1000Res 2019; 8: F1000.
Google Scholar | Crossref | Medline35. Neurath, MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14: 329–342.
Google Scholar | Crossref | Medline | ISI36. Holtmann, MH, Douni, E, Schütz, M, et al. Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn’s disease and promotes experimental colitis in vivo. Eur J Immunol 2002; 32: 3142–3151.
Google Scholar | Crossref | Medline | ISI37. Perrier, C, de Hertogh, G, Cremer, J, et al. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis 2013; 19: 246–253.
Google Scholar | Crossref | Medline38. Behm, B, Bickston, S. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2008; 1: CD006893.
Google Scholar39. Kaymakcalan, Z, Sakorafas, P, Bose, S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131: 308–316.
Google Scholar | Crossref | Medline40. Nesbitt, A, Fossati, G, Bergin, M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13: 1323–1332.
Google Scholar | Crossref | Medline | ISI41. Atreya, R, Zimmer, M, Bartsch, B, et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages. Gastroenterology 2011; 141: 2026–2038.
Google Scholar | Crossref | Medline42. Povoleri, GAM, Lalnunhlimi, S, Steel, KJA, et al. Anti-TNF treatment negatively regulates human CD4(+) T-cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype. Eur J Immunol 2020; 50: 445–458.
Google Scholar | Crossref | Medline43. Evans, HG, Roostalu, U, Walter, GJ, et al. TNF-α blockade induces IL-10 expression in human CD4+ T cells. Nat Commun 2014; 5: 3199.
Google Scholar | Crossref | Medline44. Roberts, CA, Durham, LE, Fleskens, V, et al. TNF blockade maintains an IL-10(+) phenotype in human effector CD4(+) and CD8(+) T cells. Front Immunol 2017; 8: 157.
Google Scholar | Crossref | Medline45. Vos, AC, Wildenberg, ME, Arijs, I, et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis 2012; 18: 401–408.
Google Scholar | Crossref | Medline46. Van den Brande, JM, Braat, H, van den Brink, GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 2003; 124: 1774–1785.
Google Scholar | Crossref | Medline | ISI47. Hiller, A, Biedermann, L, Fournier, N, et al. The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. PLoS ONE 2019; 14: e0211554.
Google Scholar | Crossref | Medline48. Vavricka, SR, Galván, JA, Dawson, H, et al. Expression patterns of TNFα, MAdCAM1, and STAT3 in intestinal and skin manifestations of inflammatory bowel disease. J Crohns Colitis 2018; 12: 347–354.
Google Scholar | Crossref | Medline49. Peyrin-Biroulet, L, Van Assche, G, Gómez-Ulloa, D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol 2017; 15: 25–36.
Google Scholar | Crossref | Medline50. Steeland, S, Libert, C, Vandenbroucke, RE. A new venue of TNF targeting. Int J Mol Sci 2018; 19: 1442.
Google Scholar | Crossref51. Parameswaran, N, Patial, S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010; 20: 87–103.
Google Scholar | Crossref | Medline | ISI52. Harbord, M, Eliakim, R, Bettenworth, D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2017; 11: 769–784.
Google Scholar | Crossref | Medline53. Rubin, DT, Ananthakrishnan, AN, Siegel, CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019; 114: 384–413.
Google Scholar | Crossref | Medline54. Feuerstein, JD, Isaacs, KL, Schneider, Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology 2020; 158: 1450–1461.
Google Scholar | Crossref | Medline55. Turner, D, Ruemmele, FM, Orlanski-Meyer, E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from the European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67: 257–291.
Google Schol